Dopamine News and Research

Latest Dopamine News and Research

Schizophrenia: Insight into late development of symptoms

In reports of two new studies, researchers led by Johns Hopkins say they have identified the mechanisms rooted in two anatomical brain abnormalities that may explain the onset of schizophrenia and the reason symptoms don't develop until young adulthood. Both types of anatomical glitches are influenced by a gene known as DISC1, whose mutant form was first identified in a Scottish family with a strong history of schizophrenia and related mental disorders. The findings could lead to new ways to treat, prevent or modify the disorder or its symptoms.

26 Feb 2010

Fisher Wallace Cranial Stimulator prescribed to patients suffering from depression, anxiety and insomnia

Fisher Wallace Laboratories today announced that two psychiatry professors at Columbia University, Dr. Richard Brown and Dr. Andres San Martin, have prescribed the Fisher Wallace Cranial Stimulator to more than 250 patients suffering from depression, anxiety and insomnia.

25 Feb 2010

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

PsychoGenics Inc. today announced the establishment of an exclusive alliance with Dr. Jan Kehr, an internationally recognized expert in experimental neuropharmacology, to provide specialized microdialysis services to complement PsychoGenics’ in vivo testing capabilities.

19 Feb 2010

Wyoming lawkmaker pushes for reform, Mississippi Governor bans certain over-the-counter drugs

Associated Press/CNBC: "A veteran Wyoming state senator for the third time is pushing a bill he says would offer health insurance to people who couldn't afford it on the open market and also serve as an example to the rest of the nation of how to tackle rising health care costs. Sen. Charles Scott, R-Casper, has proposed a pilot program that calls for allowing 500 participants to enroll in Medicaid beginning in July. It would be limited to people whose family income is below 250 percent of the federal poverty level — $55,125 for a family of four.

15 Feb 2010

Researchers investigate risk factors for childhood obesity

Both genetics and parents who comfort their infants with food are the focus of a study funded for $1 million by the National Institute of Diabetes and Digestion and Kidney Disease investigating risk factors for childhood obesity.

11 Feb 2010

Study could lead to new therapeutic strategies for Parkinson's disease

A new study from The Montreal Neurological Institute and Hospital - The Neuro - at McGill University is the first to discover a molecular link between Parkinson's disease and defects in the ability of nerve cells to communicate.

10 Feb 2010

FDA accepts Psyadon Pharmaceuticals' ecopipam IND for treatment of LND

Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.

9 Feb 2010

New class of compound could become effective antidepressant with minimal side effects

Chemists at Oregon State University have discovered and synthesized a new compound that in laboratory and animal tests appears to be similar to, but may have advantages over one of the most important antidepressant medications in the world.

5 Feb 2010

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

The Michael J. Fox Foundation for Parkinson's Research today announced more than $2.8 million in awards for 13 new projects to speed the discovery of biomarkers of PD.

4 Feb 2010

Dopamine plays a critical role in behavioral processes

People have typically viewed the benefits that accrue with social status primarily from the perspective of external rewards. A new paper in the February 1st issue of Biological Psychiatry, published by Elsevier suggests that there are internal rewards as well.

3 Feb 2010

Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease

Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease.

1 Feb 2010

Scientists discover mechanism that regulates prolactin hormone

A mechanism for regulating the hormone prolactin has newly been revealed by scientists at Karolinska Institutet. The results are to be published in the scientific journal Neuron, and may be significant for conditions and functions such as breast-feeding, sexual libido, and metabolism.

28 Jan 2010

Epidemiological study shows Parkinson's disease is more common among whites and Hispanics

The largest epidemiological study of Parkinson's disease in the United States has found that the disease is more common in the Midwest and the Northeast and is twice as likely to strike whites and Hispanics as blacks and Asians.

28 Jan 2010

Scott & White conducts DBS research for Parkinson's patients

At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.

27 Jan 2010

New computational model helps understand how dopamine medications affect non-motor functions

A new brain-based computational model is helping to understand how Parkinson's disease and dopamine medications-used to treat motor symptoms caused by the disease- can affect learning and attention.

21 Jan 2010

Research shows brain abnormalities develop years before Parkinson's symptoms appear

Scientists who have identified brain networks damaged in Parkinson's disease have new evidence that these systems become abnormal a few years before symptoms appear. And what's more, parts of the network appear to respond in a last ditch attempt to rescue the brain.

21 Jan 2010

Brain mechanisms behind compulsive behaviors in Parkinson's disease patients

New research unravels the brain mechanisms that underlie the ability of a standard drug treatment for Parkinson's to elicit compulsive behaviors in some patients with the disease. The study, published by Cell Press in the January 14th issue of the journal Neuron, provides fascinating new insight into the brain mechanisms that underlie a predisposition to behavioral addictions, such as pathological gambling and shopping.

18 Jan 2010

Dopamine replacement therapy causes brain dysfunction in patients with Parkinson disease, study says

People with Parkinson's Disease are more likely to display abnormal social behaviour and make poor decisions in ambiguous circumstances if they are pathological gamblers, according to research in the January issue of the European Journal of Neurology.

18 Jan 2010

New genetic risk factor for Parkinson's disease identified

An international team of doctors and human geneticists has identified a new genetic risk factor for Parkinson's disease. The institutions involved in the study were the Institute of Human Genetics of Helmholtz Zentrum München and Technische Universität München, the Neurological Clinic of Ludwig-Maximilians-Universität Munich (LMU) and the Mitochondrial Research Group of Newcastle University, Newcastle upon Tyne, UK.

18 Jan 2010

Molecules capable of reversing brain abnormalities in PD identified

Scientists identified several molecules capable of reversing the brain abnormalities of Parkinson's disease (PD), while also uncovering new clues for its origin in a study just published in the journal Disease Models and Mechanisms. PD is characterised by abnormal deposits of a brain protein called alpha-synuclein throughout the damaged brain regions, but exactly what they do there is not clear. The fact that their numbers and spreading are associated disease progression has made them, however, a major point of interest in PD research.

18 Jan 2010

Dopamine News and Research

Latest Dopamine News and Research

Schizophrenia: Insight into late development of symptoms

Fisher Wallace Cranial Stimulator prescribed to patients suffering from depression, anxiety and insomnia

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

Wyoming lawkmaker pushes for reform, Mississippi Governor bans certain over-the-counter drugs

Researchers investigate risk factors for childhood obesity

Study could lead to new therapeutic strategies for Parkinson's disease

FDA accepts Psyadon Pharmaceuticals' ecopipam IND for treatment of LND

New class of compound could become effective antidepressant with minimal side effects

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

Dopamine plays a critical role in behavioral processes

Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease

Scientists discover mechanism that regulates prolactin hormone

Epidemiological study shows Parkinson's disease is more common among whites and Hispanics

Scott & White conducts DBS research for Parkinson's patients

New computational model helps understand how dopamine medications affect non-motor functions

Research shows brain abnormalities develop years before Parkinson's symptoms appear

Brain mechanisms behind compulsive behaviors in Parkinson's disease patients

Dopamine replacement therapy causes brain dysfunction in patients with Parkinson disease, study says

New genetic risk factor for Parkinson's disease identified

Molecules capable of reversing brain abnormalities in PD identified

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Dopamine News and Research

Latest Dopamine News and Research

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Newsletters you may be interested in